Reuters: Regulatory News: UK cost agency says "no" to Celgene bone marrow drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UK cost agency says "no" to Celgene bone marrow drug Jul 10th 2013, 23:01 LONDON, July 11 | Wed Jul 10, 2013 7:01pm EDT LONDON, July 11 (Reuters) - Celgene's drug Revlimid is not worth using on Britain's state health service because of uncertainty over whether it can extend the lives of patients with serious bone marrow disorders, the country's cost agency said on Thursday. The draft guidance from the National Institute for Health and Clinical Excellence (NICE), if confirmed following a consultation process, would remove a treatment option for patients with myelodysplastic syndromes, which can lead to life-threatening diseases such as leukaemia.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions